Dr Reddys Laboratories (RDY) Common Equity (2009 - 2026)

Dr Reddys Laboratories (RDY) has reported Common Equity for 16 consecutive years, with $4.1 billion the latest figure, recorded in Q1 2026.

• Quarterly Common Equity rose 3.87% year-over-year to $4.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 billion (up 3.87% YoY) and the FY2026 annual result came in at $4.1 billion, up 3.87% from the prior year.
• Common Equity grew to $4.1 billion in Q1 2026 per RDY's latest filing, from $3.9 billion in the prior quarter.
• Over the last five years, Common Equity for RDY reached as high as $4.1 billion in Q1 2026 and fell as low as $2.4 billion in Q2 2022.
• A 4-year average of $3.2 billion and a median of $3.0 billion in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity gained 22.4% — and 2026, when it rose 3.87%.
• Year by year, Common Equity stood at $2.4 billion in 2022, then rose by 22.4% to $3.0 billion in 2023, then soared by 30.58% to $3.9 billion in 2025, then advanced by 3.87% to $4.1 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $4.1 billion, $3.9 billion, and $3.0 billion for Q1 2026, Q1 2025, and Q2 2023 respectively.